Adjuvant and neoadjuvant therapies in high risk localized prostate cancer

被引：0
作者：
Giannakopoulos, X.
Stagikas, D.
Charalabopoulos, A.
Sofikitis, N.
Charalabopoulos, K.
机构：
[1] Univ Ioannina, Dept Physiol, Clin Unit, Fac Med, GR-45221 Ioannina, Greece
[2] Univ Ioannina, Dept Urol, GR-45221 Ioannina, Greece
[3] Peterborough Hosp, Dept Surg, Peterborough, Cambs, England
来源：
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH | 2006年 / 25卷 / 04期
关键词：
prostate cancer; adjuvant therapy; neoadjuvant therapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In this review article adjuvant and neoadjuvant therapies in patients at high risk for localized prostate cancer are presented in some detail. Adjuvant hormone therapy by antiandrogens as well as antineoplastic chemotherapeutic agents such as estramustine and taxanes are referred. Neoadjuvant therapies in addition to systemic therapy before or after local treatment for prostate cancer may improve the outcome of high risk patients otherwise destined to treatment fail. Data regarding some substances used in neoadjuvant therapies such as androgen deprivation therapy and use of rapamycin with its analogs, as well as some novel therapeutic approach strategies are also discussed.
引用
收藏
页码：469 / 473
页数：5
相关论文
共 49 条
[1]   PSA bouncing after short term androgen deprivation and 3D-conformal radiotherapy for localized prostate adenocarcinoma and the relationship with the kinetics of testosterone [J].
Akyol, F ;
Ozyigit, G ;
Selek, U ;
Karabulut, E .
EUROPEAN UROLOGY, 2005, 48 (01) :40-45
[2]  
Baltogiannis D, 2005, EXP ONCOL, V27, P91
[3]  
Baltogiannis D, 2004, EXP ONCOL, V26, P185
[4]   Interleukin 2 gene therapy for prostate cancer: Phase I clinical trial and basic biology [J].
Belldegrun, A ;
Tso, CL ;
Zisman, A ;
Naitoh, J ;
Said, J ;
Pantuck, AJ ;
Hinkel, A ;
de Kernion, J ;
Figlin, R .
HUMAN GENE THERAPY, 2001, 12 (08) :883-892
[5]   Neoadjuvant estramustine and etoposide followed by concurrent estramustine and definitive radiotherapy for locally advanced prostate cancer: Feasibility and preliminary results [J].
Ben-Josef, E ;
Porter, AT ;
Han, S ;
Mertens, W ;
Chuba, P ;
Fontana, J ;
Hussain, M .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 49 (03) :699-703
[6]   The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer [J].
Berry, WR .
UROLOGY, 2005, 65 (6A) :2-7
[7]   Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin [J].
Bolla, M ;
Gonzalez, D ;
Warde, P ;
Dubois, JB ;
Mirimanoff, RO ;
Storme, G ;
Bernier, J ;
Kuten, A ;
Sternberg, C ;
Gil, T ;
Collette, L ;
Pierart, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (05) :295-300
[8]   Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial [J].
Bolla, M ;
Collette, L ;
Blank, L ;
Warde, P ;
Dubois, JB ;
Mirimanoff, RO ;
Storme, G ;
Bernier, J ;
Kuten, A ;
Sternberg, C ;
Mattelaer, J ;
Torecilla, JL ;
Pfeffer, JR ;
Cutajar, CL ;
Zurlo, A ;
Pierart, M .
LANCET, 2002, 360 (9327) :103-108
[9]   PROGRESSION AND COMPLICATIONS AFTER EXTERNAL BEAM RADIATION-THERAPY FOR CARCINOMA OF PROSTATE [J].
BRAUSI, M ;
SOLOWAY, MS .
UROLOGY, 1989, 34 (03) :115-119
[10]   Adjuvant and neoadjuvant therapy in prostate cancer [J].
Chay, C ;
Smith, DC .
SEMINARS IN ONCOLOGY, 2001, 28 (01) :3-12
12345